A phase I study of bortezomib and temozolomide in patients with advanced solid tumors

被引：0
|
作者：
J. Portnow
P. Frankel
S. Koehler
P. Twardowski
S. Shibata
C. Martel
R. Morgan
M. Cristea
W. Chow
D. Lim
V. Chung
K. Reckamp
L. Leong
T. W. Synold
机构：
[1] City of Hope,Department of Medical Oncology
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Bortezomib; Temozolomide; Phase I; Pharmacokinetics; Hepatic enzyme-inducing anticonvulsants;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：505 / 514
页数：9
相关论文
共 50 条
  • [1] A phase I study of bortezomib and temozolomide in patients with advanced solid tumors
    Portnow, J.
    Frankel, P.
    Koehler, S.
    Twardowski, P.
    Shibata, S.
    Martel, C.
    Morgan, R.
    Cristea, M.
    Chow, W.
    Lim, D.
    Chung, V.
    Reckamp, K.
    Leong, L.
    Synold, T. W.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (02) : 505 - 514
  • [2] A phase I study of bortezomib (BTZ) and temozolomide (TMZ) in patients with advanced solid tumors
    Portnow, J.
    Koehler, S.
    Cristea, M. C.
    Chow, W. A.
    Chung, V. M.
    Lim, D.
    Morgan, R.
    Shibata, S.
    Frankel, P. H.
    Synold, T. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] A phase I study of bortezomib plus irinotecan in patients with advanced solid tumors
    Ryan, David R.
    O'Neil, Bell H.
    Supko, Jeffrey G.
    Lima, Carlo M. Rocha
    Dees, E. Claire
    Appleman, Leonard J.
    Clark, Jeffrey
    Fidias, Phinos
    Orlowski, Robert Z.
    Kashala, Oscar
    Eder, Joseph R.
    Cusack, James C., Jr.
    CANCER, 2006, 107 (11) : 2688 - 2697
  • [4] A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors
    Dustin A. Deming
    Jacob Ninan
    Howard H. Bailey
    Jill M. Kolesar
    Jens Eickhoff
    Joel M. Reid
    Matthew M. Ames
    Renee M. McGovern
    Dona Alberti
    Rebecca Marnocha
    Igor Espinoza-Delgado
    John Wright
    George Wilding
    William R. Schelman
    Investigational New Drugs, 2014, 32 : 323 - 329
  • [5] A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors
    Deming, Dustin A.
    Ninan, Jacob
    Bailey, Howard H.
    Kolesar, Jill M.
    Eickhoff, Jens
    Reid, Joel M.
    Ames, Matthew M.
    McGovern, Renee M.
    Alberti, Dona
    Marnocha, Rebecca
    Espinoza-Delgado, Igor
    Wright, John
    Wilding, George
    Schelman, William R.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (02) : 323 - 329
  • [6] Phase I trial of bortezomib in combination with ocetaxel in patients with advanced solid tumors
    Messersmith, WA
    Baker, SD
    Lassiter, L
    Sullivan, RA
    Dinh, K
    Almuete, VI
    Wright, JJ
    Donehower, RC
    Carducci, MA
    Armstrong, DK
    CLINICAL CANCER RESEARCH, 2006, 12 (04) : 1270 - 1275
  • [7] Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial
    John Hayslip
    Uzair Chaudhary
    Mark Green
    Mario Meyer
    Steven Dunder
    Carol Sherman
    Shanta Salzer
    Andrew Kraft
    Alberto J Montero
    BMC Cancer, 7
  • [8] Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial
    Hayslip, John
    Chaudhary, Uzair
    Green, Mark
    Meyer, Mario
    Dunder, Steven
    Sherman, Carol
    Salzer, Shanta
    Kraft, Andrew
    Montero, Alberto J.
    BMC CANCER, 2007, 7 (1)
  • [9] Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors
    Cohen, Steven J.
    Engstrom, Paul F.
    Lewis, Nancy L.
    Langer, Corey J.
    McLaughlin, Susan
    Beard, Mary
    Weiner, Louis M.
    Meropol, Neal J.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (01): : 1 - 5
  • [10] A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy
    Christopher Lieu
    Laura Chow
    A. Scott Pierson
    S. Gail Eckhardt
    Cindy L. O’Bryant
    Mark Morrow
    Zung Vu Tran
    John J. Wright
    Lia Gore
    Investigational New Drugs, 2009, 27 : 53 - 62
12345